Live Analyst Rating Changes 1844 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Phil Nadeau
TD
Phil Nadeau
TD Cowen
Wall Street Analyst
★★★☆☆
#1112
on 13Foresight · ranked by our own returns
55%
Success Rate
+4.7%
Average Return
21 of 38 calls profitable · -1.6% vs benchmark
📈 Across the calls we could measure, roughly 55% of Phil Nadeau's ratings turned a profit when each position was held for 1 year — averaging +4.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

126 Buy 4 Hold 0 Sell
Phil's Stock Coverage 35 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
RYTM
Rhythm Pharmaceuticals
 Jun 17, 2026 BUY Strong Buy
+22.1% avg upside
19 analysts
$130.00
28.29% Upside
 +0.0%
VYGR
Voyager Therapeutics
 Jun 17, 2026 BUY Strong Buy
+283.4% avg upside
23 analysts
 — ·
ELVN
Enliven Therapeutics
 Jun 11, 2026 BUY Strong Buy
+5.8% avg upside
14 analysts
 — +11.7%
IPSC
Century Therapeutics
 Jun 08, 2026 BUY Strong Buy
+131.8% avg upside
11 analysts
 — +6.1%
CABA
Cabaletta Bio
 Jun 03, 2026 BUY Strong Buy
+367.3% avg upside
16 analysts
 — ·
BMRN
BioMarin Pharmaceutical
 May 21, 2026 BUY Strong Buy
+70.1% avg upside
52 analysts
$120.00
114.75% Upside
 +3.3%
BIIB
Biogen
 May 14, 2026 BUY Buy
+23.7% avg upside
51 analysts
$215.00
7.64% Upside
 +4.4%
KURA
Kura Oncology
 May 12, 2026 BUY Strong Buy
+155.2% avg upside
26 analysts
 — -1.1%
AURA
Aura Biosciences Inc
 May 11, 2026 BUY Strong Buy
+211.9% avg upside
9 analysts
 — -21.7%
MLTX
MoonLake Immunotherapeutics
 May 11, 2026 BUY Strong Buy
+37.7% avg upside
20 analysts
 — +1.9%
ANNX
Annexon Biosciences
 May 07, 2026 BUY Strong Buy
+176.7% avg upside
13 analysts
 — -11.2%
SRZN
Surrozen
 May 07, 2026 BUY Buy
+47.9% avg upside
7 analysts
 — -21.8%
VIR
Vir Biotechnology
 May 07, 2026 BUY Strong Buy
+177.3% avg upside
16 analysts
 — +0.3%
NBIX
Neurocrine
 May 05, 2026 BUY Strong Buy
+6.5% avg upside
37 analysts
$200.00
23.75% Upside
 +17.2%
EDIT
Editas Medicine
 May 05, 2026 BUY Buy
+392.7% avg upside
33 analysts
 — -13.0%
VRTX
Vertex Pharmaceuticals
 May 05, 2026 BUY Strong Buy
-4.8% avg upside
61 analysts
$525.00
12.50% Upside
 +10.0%
SNDX
Syndax Pharmaceuticals
 Apr 30, 2026 BUY Strong Buy
+86.7% avg upside
27 analysts
 — -11.2%
CBIO
Crescent Biopharma
 Apr 29, 2026 BUY Strong Buy
+26.8% avg upside
17 analysts
 — ·
XOMA
XOMA Royalty Corporation
 Mar 18, 2026 HOLD Buy
-46.6% avg upside
11 analysts
 — +52.4%
ATRA
Atara Biotherapeutics
 Mar 09, 2025 BUY Buy
+75.4% avg upside
18 analysts
 — +8.4%
SYRS
Syros Pharmaceuticals
 Nov 13, 2024 HOLD Buy
+11749900.0% avg upside
9 analysts
 — -99.8%
LKFT
Lakefront Biotherapeutics
 Oct 31, 2024 BUY Hold
+266.6% avg upside
24 analysts
 — ·
LENZ
LENZ Therapeutics
 Mar 22, 2024 HOLD Buy
+302.1% avg upside
17 analysts
 — +63.5%
KRRO
Korro Bio
 Feb 13, 2023 HOLD Strong Buy
+99.1% avg upside
19 analysts
 — +40.7%
GILD
Gilead Sciences
 Feb 04, 2021 BUY Strong Buy
-5.3% avg upside
66 analysts
$75.00
39.99% Downside
 +1.2%
QTTB
Q32 Bio
 Nov 09, 2020 BUY Buy
+331.9% avg upside
24 analysts
 — -37.6%
ALLO
Allogene Therapeutics
 Aug 07, 2019 BUY Strong Buy
+634.9% avg upside
28 analysts
 — +27.2%
RCKT
Rocket Pharmaceuticals
 Feb 26, 2019 BUY Buy
+381.9% avg upside
29 analysts
 — +20.5%
REGN
Regeneron
 Feb 06, 2019 HOLD Strong Buy
+26.8% avg upside
57 analysts
$385.00
37.17% Downside
 -4.1%
LRMR
Larimar Therapeutics
 Jan 17, 2019 HOLD Strong Buy
+403.3% avg upside
21 analysts
 — -74.3%
GNCAQ
Genocea Biosciences
 Nov 02, 2018 BUY Strong Buy
+573999900.0% avg upside
10 analysts
$16.00
1599999900.05% Upside
 ·
AMGN
Amgen
 Jul 26, 2018 BUY Buy
-12.8% avg upside
57 analysts
$205.00
40.49% Downside
 -6.9%
LXRX
Lexicon Pharmaceuticals
 May 03, 2016 HOLD Buy
+90.8% avg upside
9 analysts
 — +23.2%
UTHR
United Therapeutics
 Apr 28, 2016 BUY Strong Buy
-18.9% avg upside
26 analysts
$185.00
65.56% Downside
 +19.9%
SRPT
Sarepta Therapeutics
 Aug 07, 2015 HOLD Buy
+241.4% avg upside
49 analysts
 — -18.8%
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Phil Nadeau — Frequently Asked Questions
How accurate are Phil Nadeau's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Phil's ratings were profitable over a one-year hold, with an average return of +4.7% per rating, or -1.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Phil ranked on 13Foresight?
Phil Nadeau is currently ranked #1112 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Phil cover?
Phil most recently has ratings on RYTM, VYGR, ELVN, IPSC, CABA, BMRN, BIIB, KURA, AURA, MLTX, ANNX, SRZN and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.